Related Experiment Video
Updated: Jul 15, 2026
06:15
Anterior High-Resolution Optical Coherence Tomography in the Diagnosis and Therapeutic Monitoring of Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
Mitomycin C and conjunctival autograft for recurrent pterygium
Uğur E Altiparmak1, Yasemin Aslan Katircioğlu, Ramazan Yağci
1Department of Ophthalmology, Ankara Training and Research Hospital, Ankara, Turkey. ealtiparmak@hotmail.com
International Ophthalmology
|May 9, 2007
Summary
Intraoperative low-dose Mitomycin-C with conjunctival autograft effectively treats recurrent pterygium, significantly reducing recurrence rates. This combined approach demonstrated minimal complications in the observed cases.
Area of Science:
- Ophthalmology
- Surgical Techniques
Background:
- Recurrent pterygium poses a significant challenge in ophthalmic surgery.
- Existing treatments often have high recurrence rates and potential complications.
Purpose of the Study:
- To evaluate the efficacy of combining low-dose Mitomycin-C with conjunctival autograft for recurrent pterygium.
- To assess the complication profile of this combined surgical approach.
Main Methods:
- A cohort of 15 eyes with recurrent pterygium underwent pterygium and subconjunctival fibrous tissue excision.
- Intraoperative application of Mitomycin-C (0.2 mg/ml) for 3 minutes was performed.
- Conjunctival autograft harvested from the superotemporal bulbar conjunctiva was utilized.
Main Results:
- A low recurrence rate of 13.3% (2 out of 15 eyes) was observed during the mean follow-up of 21 months.
- Graft edema was the primary complication, occurring in 13.3% of eyes and resolving with pressure patching.
- No instances of graft necrosis, scleral melting, or failure of revascularization were reported.
Conclusions:
- The combination of intraoperative Mitomycin-C and conjunctival autograft is an effective strategy for managing recurrent pterygium.
- This method offers a favorable safety profile with a low incidence of significant complications.